Journal of Clinical Virology
Volume 53, Issue 2 , Pages 97-105 , February 2012

Ten years of human metapneumovirus research

  • F. Feuillet

      Affiliations

    • Laboratoire de Virologie et Pathologie Humaine (VirPath), EMR 4610, Université Claude Bernard Lyon 1 – Hospices civils de Lyon, Faculté de Médecine RTH Laennec, 7, rue Guillaume Paradin, Lyon 69372, France
    • Centre de recherche en infectiologie, Université Laval and Centre Hospitalier Universitaire de Québec, CHUQ-CHUL, 2705 Blvd Laurier, Sainte-Foy, Quebec, Canada G1V4G2
    • ,
  • B. Lina

      Affiliations

    • Laboratoire de Virologie et Pathologie Humaine (VirPath), EMR 4610, Université Claude Bernard Lyon 1 – Hospices civils de Lyon, Faculté de Médecine RTH Laennec, 7, rue Guillaume Paradin, Lyon 69372, France
    • ,
  • M. Rosa-Calatrava

      Affiliations

    • Laboratoire de Virologie et Pathologie Humaine (VirPath), EMR 4610, Université Claude Bernard Lyon 1 – Hospices civils de Lyon, Faculté de Médecine RTH Laennec, 7, rue Guillaume Paradin, Lyon 69372, France
    • Corresponding Author InformationCorresponding author at: Laboratoire de Virologie et Pathologie Humaine (VirPath), Université Claude Bernard Lyon 1 – Hospices civils de Lyon, Faculté de Médecine RTH Laennec, 7, rue Guillaume Paradin, Lyon 69372, France.
    • ,
  • G. Boivin

      Affiliations

    • Laboratoire de Virologie et Pathologie Humaine (VirPath), EMR 4610, Université Claude Bernard Lyon 1 – Hospices civils de Lyon, Faculté de Médecine RTH Laennec, 7, rue Guillaume Paradin, Lyon 69372, France
    • Centre de recherche en infectiologie, Université Laval and Centre Hospitalier Universitaire de Québec, CHUQ-CHUL, 2705 Blvd Laurier, Sainte-Foy, Quebec, Canada G1V4G2
    • Corresponding Author InformationCorresponding author.

Received 29 July 2011 ,Revised 5 October 2011 ,Accepted 10 October 2011.

References 

  1. van den Hoogen BG, de Jong JC, Groen J, Kuiken T, de Groot R, Fouchier RA, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med. 2001;7:719–724
  2. van den Hoogen BG, Herfst S, Sprong L, Cane PA, Forleo-Neto E, de Swart RL, et al. Antigenic and genetic variability of human metapneumoviruses. Emerg Infect Dis. 2004;10:658–666
  3. Huck B, Egger M, Bertz H, Peyerl-Hoffman G, Kern WV, Neumann-Haefelin D, et al. Human metapneumovirus infection in a hematopoietic stem cell transplant recipient with relapsed multiple myeloma and rapidly progressing lung cancer. J Clin Microbiol. 2006;44:2300–2303
  4. Skiadopoulos MH, Biacchesi S, Buchholz UJ, Riggs JM, Surman SR, Amaro-Carambot E, et al. The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatedness. J Virol. 2004;78:6927–6937
  5. van den Hoogen BG, Bestebroer TM, Osterhaus AD, Fouchier RA. Analysis of the genomic sequence of a human metapneumovirus. Virology. 2002;295:119–132
  6. Freymuth F, Vabret A, Lebon P, Legrand L, Bach N, Brouard J, et al. Le Métapneumovirus humain. Virologie. 2004;8:413–423
  7. Kahn JS. Epidemiology of human metapneumovirus. Clin Microbiol Rev. 2006;19:546–557
  8. Palacios G, Lowenstine LJ, Cranfield MR, Gilardi KV, Spelman L, Lukasik-Braum M, et al. Human metapneumovirus infection in wild mountain gorillas, Rwanda. Emerg Infect Dis. 2011;17:711–713
  9. Louie JK, Schnurr DP, Pan CY, Kiang D, Carter C, Tougaw S, et al. A summer outbreak of human metapneumovirus infection in a long-term-care facility. J Infect Dis. 2007;196:705–708
  10. Papenburg J, Boivin G. The distinguishing features of human metapneumovirus and respiratory syncytial virus. Rev Med Virol. 2010;20:245–260
  11. Boivin G, De Serres G, Hamelin ME, Cote S, Argouin M, Tremblay G, et al. An outbreak of severe respiratory tract infection due to human metapneumovirus in a long-term care facility. Clin Infect Dis. 2007;44:1152–1158
  12. Darniot M, Pitoiset C, Petrella T, Aho S, Pothier P, Manoha C. Age-associated aggravation of clinical disease after primary metapneumovirus infection of BALB/c mice. J Virol. 2009;83:3323–3332
  13. de Graaf M. Metapneumovirus: determinants of host range and replication. Doctoral thesis; 2009. <http://repub.eur.nl/res/pub/16401>.
  14. Tollefson SJ, Cox RG, Williams JV. Studies of culture conditions and environmental stability of human metapneumovirus. Virus Res. 2010;151:54–59
  15. Reina J, Ferres F, Alcoceba E, Mena A, de Gopegui ER, Figuerola J. Comparison of different cell lines and incubation times in the isolation by the shell vial culture of human metapneumovirus from pediatric respiratory samples. J Clin Virol. 2007;40:46–49
  16. Schildgen V, Lusebrink J, Ditt V, Tillmann R, Simon A, Muller A, et al. Human HepG2 cells support respiratory syncytial virus and human metapneumovirus replication. J Virol Methods. 2010;163:74–81
  17. Boivin G, Abed Y, Pelletier G, Ruel L, Moisan D, Cote S, et al. Virological features and clinical manifestations associated with human metapneumovirus: a new paramyxovirus responsible for acute respiratory-tract infections in all age groups. J Infect Dis. 2002;186:1330–1334
  18. Kukavica-Ibrulj I, Boivin G. Detection of human metapneumovirus antigens in nasopharyngeal aspirates using an enzyme immunoassay. J Clin Virol. 2009;44:88–90
  19. Jun KR, Woo YD, Sung H, Kim MN. Detection of human metapneumovirus by direct antigen test and shell vial cultures using immunofluorescent antibody staining. J Virol Methods. 2008;152:109–111
  20. Maertzdorf J, Wang CK, Brown JB, Quinto JD, Chu M, de Graaf M, et al. Real-time reverse transcriptase PCR assay for detection of human metapneumoviruses from all known genetic lineages. J Clin Microbiol. 2004;42:981–986
  21. Gharabaghi F, Hawan A, Drews SJ, Richardson SE. Evaluation of multiple commercial molecular and conventional diagnostic assays for the detection of respiratory viruses in children. Clin Microbiol Infect. 2011;Article first published online: 24 june 2011, Early View
  22. Terrier OCG, Lina B. La génétique inverse chez les paramyxovirus: applications et perspectives. Virologie. 2008;12:15–25
  23. Thammawat S, Sadlon TA, Hallsworth PG, Gordon DL. Role of cellular glycosaminoglycans and charged regions of viral G protein in human metapneumovirus infection. J Virol. 2008;82:11767–11774
  24. Cseke G, Maginnis MS, Cox RG, Tollefson SJ, Podsiad AB, Wright DW, et al. Integrin alphavbeta1 promotes infection by human metapneumovirus. Proc Natl Acad Sci USA. 2009;106:1566–1571
  25. Smith EC, Popa A, Chang A, Masante C, Dutch RE. Viral entry mechanisms: the increasing diversity of paramyxovirus entry. FEBS J. 2009;276:7217–7227
  26. White JM, Delos SE, Brecher M, Schornberg K. Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. Crit Rev Biochem Mol Biol. 2008;43:189–219
  27. Hernandez LD, Hoffman LR, Wolfsberg TG, White JM. Virus–cell and cell–cell fusion. Ann Rev Cell Dev Biol. 1996;12:627–661
  28. Kielian M, Rey FA. Virus membrane-fusion proteins: more than one way to make a hairpin. Nat Rev Microbiol. 2006;4:67–76
  29. Brändén C-I, Tooze J. Introduction to protein structure. 2nd ed.. New York: Garland Pub; 1999;
  30. Gardner AE, Dutch RE. A conserved region in the F(2) subunit of paramyxovirus fusion proteins is involved in fusion regulation. J Virol. 2007;81:8303–8314
  31. Cseke G, Wright DW, Tollefson SJ, Johnson JE, Crowe JE, Williams JV. Human metapneumovirus fusion protein vaccines that are immunogenic and protective in cotton rats. J Virol. 2007;81:698–707
  32. Gardner AE, Martin KL, Dutch RE. A conserved region between the heptad repeats of paramyxovirus fusion proteins is critical for proper F protein folding. Biochemistry. 2007;46:5094–5105
  33. Schowalter RM, Chang A, Robach JG, Buchholz UJ, Dutch RE. Low-pH triggering of human metapneumovirus fusion: essential residues and importance in entry. J Virol. 2009;83:1511–1522
  34. Herfst S, Mas V, Ver LS, Wierda RJ, Osterhaus AD, Fouchier RA, et al. Low-pH-induced membrane fusion mediated by human metapneumovirus F protein is a rare, strain-dependent phenomenon. J Virol. 2008;82:8891–8895
  35. Easton AJ, Domachowske JB, Rosenberg HF. Animal pneumoviruses: molecular genetics and pathogenesis. Clin Microbiol Rev. 2004;17:390–412
  36. Mackay IM, Jacob KC, Woolhouse D, Waller K, Syrmis MW, Whiley DM, et al. Molecular assays for detection of human metapneumovirus. J Clin Microbiol. 2003;41:100–105
  37. Vargas SO, Kozakewich HP, Perez-Atayde AR, McAdam AJ. Pathology of human metapneumovirus infection: insights into the pathogenesis of a newly identified respiratory virus. Pediatr Dev Pathol. 2004;7:478–486
  38. Wyde PR, Chetty SN, Jewell AM, Boivin G, Piedra PA. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. Antiviral Res. 2003;60:51–59
  39. Hamelin ME, Prince GA, Boivin G. Effect of ribavirin and glucocorticoid treatment in a mouse model of human metapneumovirus infection. Antimicrob Agents Chemother. 2006;50:774–777
  40. Graci JD, Cameron CE. Mechanisms of action of ribavirin against distinct viruses. Rev Med Virol. 2006;16:37–48
  41. Bonney D, Razali H, Turner A, Will A. Successful treatment of human metapneumovirus pneumonia using combination therapy with intravenous ribavirin and immune globulin. Br J Haematol. 2009;145:667–669
  42. Group TI-RS. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531–537
  43. Ulbrandt ND, Ji H, Patel NK, Riggs JM, Brewah YA, Ready S, et al. Isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo. J Virol. 2006;80:7799–7806
  44. Hamelin ME, Couture C, Sackett M, Kiener P, Suzich J, Ulbrandt N, et al. The prophylactic administration of a monoclonal antibody against human metapneumovirus attenuates viral disease and airways hyperresponsiveness in mice. Antivir Ther. 2008;13:39–46
  45. Hamelin ME, Gagnon C, Prince GA, Kiener P, Suzich J, Ulbrandt N, et al. Prophylactic and therapeutic benefits of a monoclonal antibody against the fusion protein of human metapneumovirus in a mouse model. Antiviral Res. 2010;88:31–37
  46. Williams IG. Enfuvirtide (Fuzeon): the first fusion inhibitor. Int J Clin Pract. 2003;57:890–897
  47. Cianci C, Meanwell N, Krystal M. Antiviral activity and molecular mechanism of an orally active respiratory syncytial virus fusion inhibitor. J Antimicrob Chemother. 2005;55:289–292
  48. Deffrasnes C, Hamelin ME, Prince GA, Boivin G. Identification and evaluation of a highly effective fusion inhibitor for human metapneumovirus. Antimicrob Agents Chemother. 2008;52:279–287
  49. Grassmann R, Jeang KT. The roles of microRNAs in mammalian virus infection. Biochim Biophys Acta. 2008;1779:706–711
  50. DeVincenzo J, Cehelsky JE, Alvarez R, Elbashir S, Harborth J, Toudjarska I, et al. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res. 2008;77:225–231
  51. Alvarez R, Elbashir S, Borland T, Toudjarska I, Hadwiger P, John M, et al. RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. Antimicrob Agents Chemother. 2009;53:3952–3962
  52. Deffrasnes C, Cavanagh MH, Goyette N, Cui K, Ge Q, Seth S, et al. Inhibition of human metapneumovirus replication by small interfering RNA. Antivir Ther. 2008;13:821–832
  53. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol. 1969;89:405–421
  54. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89:422–434
  55. Ottolini MG, Porter DD, Hemming VG, Prince GA. Enhanced pulmonary pathology in cotton rats upon challenge after immunization with inactivated parainfluenza virus 3 vaccines. Viral Immunol. 2000;13:231–236
  56. De Swart RL, Kuiken T, Timmerman HH, van Amerongen G, Van Den Hoogen BG, Vos HW, et al. Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent RSV infection. J Virol. 2002;76:11561–11569
  57. Hamelin ME, Couture C, Sackett MK, Boivin G. Enhanced lung disease and Th2 response following human metapneumovirus infection in mice immunized with the inactivated virus. J Gen Virol. 2007;88:3391–3400
  58. de Swart RL, van den Hoogen BG, Kuiken T, Herfst S, van Amerongen G, Yuksel S, et al. Immunization of macaques with formalin-inactivated human metapneumovirus induces hypersensitivity to hMPV infection. Vaccine. 2007;25:8518–8528
  59. Biacchesi S, Skiadopoulos MH, Tran KC, Murphy BR, Collins PL, Buchholz UJ. Recovery of human metapneumovirus from cDNA: optimization of growth in vitro and expression of additional genes. Virology. 2004;321:247–259
  60. Buchholz UJ, Nagashima K, Murphy BR, Collins PL. Live vaccines for human metapneumovirus designed by reverse genetics. Expert Rev Vaccines. 2006;5:695–706
  61. Biacchesi S, Skiadopoulos MH, Yang L, Lamirande EW, Tran KC, Murphy BR, et al. Recombinant human Metapneumovirus lacking the small hydrophobic SH and/or attachment G glycoprotein: deletion of G yields a promising vaccine candidate. J Virol. 2004;78:12877–12887
  62. Buchholz UJ, Biacchesi S, Pham QN, Tran KC, Yang L, Luongo CL, et al. Deletion of M2 gene open reading frames 1 and 2 of human metapneumovirus: effects on RNA synthesis, attenuation, and immunogenicity. J Virol. 2005;79:6588–6597
  63. Tang RS, Schickli JH, MacPhail M, Fernandes F, Bicha L, Spaete J, et al. Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3′ proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity. J Virol. 2003;77:10819–10828
  64. Tang RS, Mahmood K, Macphail M, Guzzetta JM, Haller AA, Liu H, et al. A host-range restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus (hMPV) fusion protein elicits protective immunity in African green monkeys. Vaccine. 2005;23:1657–1667
  65. Pham QN, Biacchesi S, Skiadopoulos MH, Murphy BR, Collins PL, Buchholz UJ. Chimeric recombinant human metapneumoviruses with the nucleoprotein or phosphoprotein open reading frame replaced by that of avian metapneumovirus exhibit improved growth in vitro and attenuation in vivo. J Virol. 2005;79:15114–15122
  66. Skiadopoulos MH, Biacchesi S, Buchholz UJ, Amaro-Carambot E, Surman SR, Collins PL, et al. Individual contributions of the human metapneumovirus F, G, and SH surface glycoproteins to the induction of neutralizing antibodies and protective immunity. Virology. 2006;345:492–501
  67. Herfst S, de Graaf M, Schrauwen EJ, Ulbrandt ND, Barnes AS, Senthil K, et al. Immunization of Syrian golden hamsters with F subunit vaccine of human metapneumovirus induces protection against challenge with homologous or heterologous strains. J Gen Virol. 2007;88:2702–2709
  68. Herfst S, Schrauwen EJ, de Graaf M, van Amerongen G, van den Hoogen BG, de Swart RL, et al. Immunogenicity and efficacy of two candidate human metapneumovirus vaccines in cynomolgus macaques. Vaccine. 2008;26:4224–4230
  69. Bembridge GP, Rodriguez N, Garcia-Beato R, Nicolson C, Melero JA, Taylor G. DNA encoding the attachment (G) or fusion (F) protein of respiratory syncytial virus induces protection in the absence of pulmonary inflammation. J Gen Virol. 2000;81:2519–2523
  70. Vuola JM, Keating S, Webster DP, Berthoud T, Dunachie S, Gilbert SC, et al. Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J Immunol. 2005;174:449–455
  71. Safdar A. Immune modulatory activity of ribavirin for serious human metapneumovirus disease: early i.v. therapy may improve outcomes in immunosuppressed SCT recipients. Bone Marrow Transplant. 2008;41:707–708
  72. Raza K, Ismailjee SB, Crespo M, Studer SM, Sanghavi S, Paterson DL, et al. Successful outcome of human metapneumovirus (hMPV) pneumonia in a lung transplant recipient treated with intravenous ribavirin. J Heart Lung Transplant. 2007;26:862–864
  73. Kamble RT, Bollard C, Demmler G, LaSala PR, Carrum G. Human metapneumovirus infection in a hematopoietic transplant recipient. Bone Marrow Transplant. 2007;40:699–700
  74. Wyde PR, Moylett EH, Chetty SN, Jewell A, Bowlin TL, Piedra PA. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by NMSO3 in tissue culture assays. Antiviral Res. 2004;63:51–59
  75. Krusat T, Streckert HJ. Heparin-dependent attachment of respiratory syncytial virus (RSV) to host cells. Arch Virol. 1997;142:1247–1254
  76. Yim KC, Cragin RP, Boukhvalova MS, Blanco JC, Hamlin ME, Boivin G, et al. Human metapneumovirus: enhanced pulmonary disease in cotton rats immunized with formalin-inactivated virus vaccine and challenged. Vaccine. 2007;25:5034–5040
  77. Biacchesi S, Pham QN, Skiadopoulos MH, Murphy BR, Collins PL, Buchholz UJ. Infection of nonhuman primates with recombinant human metapneumovirus lacking the SH, G, or M2-2 protein categorizes each as a nonessential accessory protein and identifies vaccine candidates. J Virol. 2005;79:12608–12613

PII: S1386-6532(11)00418-5

doi: 10.1016/j.jcv.2011.10.002

Journal of Clinical Virology
Volume 53, Issue 2 , Pages 97-105 , February 2012

Article Tools

* Image Usage & Resolution